Phase II Trial of Elderly Patients With Newly Diagnosed Multiple Myeloma
MarÃa-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology Meeting.
Clinical Pearls
MarÃa-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology Meeting.
- The GEM2010MAS65 trial compared sequential and alternating administration of bortezomib, melphalan, and prednisone and lenalidomide plus dexamethasone in elderly patients with newly diagnosed multiple myeloma
- The alternating scheme showed superior efficacy in terms of complete remission
- Longer follow-up is needed
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Supportive Care Helps Manage AEs With Teclistamab in R/R Multiple Myeloma
December 13th 2024During a Case-Based Roundtable® event, Hana Safah, MD, discussed updated data and adverse event management related to teclistamab in patients with multiple myeloma in the second article of a 2-part series.
Read More
